论文部分内容阅读
目的为探讨乙肝特异性细胞毒Ｔ淋巴细胞（ＣＴＬ）对慢性乙型肝炎（ＣＨＢ）的治疗作用。方法将６３例ＣＨＢ患者随机分为两组，治疗组采用一般保肝药物治疗另加乙肝特异性ＣＴＬ静脉回输，每周１次，６次为１疗程。对照组采用一般保肝药物治疗。结果治疗组ＨＢｅＡｇ与ＨＢＶ－ＤＮＡ阴转率分别为４４．８％与３７．９％，对照组的阴转率分别为１５．４％与１０．０％。两者比较差异有显著性（Ｐ＜０．０５）。结论本疗法抗乙肝病毒作用较为明显，无毒副作用，是值得推广的新免疫疗法。
Objective To investigate the therapeutic effect of hepatitis B-specific cytotoxic T lymphocytes (CTL) on chronic hepatitis B (CHB). Methods Sixty-three patients with CHB were randomly divided into two groups. The treatment group received general liver-protection drug plus intravenous CTL infusion once a week, six times for one course of treatment. Control group using the general liver drug treatment. Results The negative conversion rates of HBeAg and HBV-DNA in the treatment group were 44.8% and 37.9% respectively, while the negative conversion rates in the control group were 15.4% and 10.0% respectively. The difference was significant (P <0.05). Conclusion The anti-hepatitis B virus therapy is more obvious and has no toxic and side effects. It is worth promoting new immunotherapy.